QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oppenheimer-maintains-outperform-on-harpoon-therapeuticsto-outperform

Oppenheimer analyst Hartaj Singh maintains Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Outperform.

 merck-posts-surprise-quarterly-profit-against-an-expected-loss-oncology-and-vaccines-drive-growth

Merck reports fourth quarter 2023 sales of $14.63 billion, a 6% YoY increase, beating estimates. Explore oncology, vaccines, an...

 investor-optimism-around-keytruda-drives-merck-stock-to-golden-cross-ahead-of-earnings

Merck stock has gained 20% since Nov. 28; a technical signal suggests the rally isn't over. Keytruda approvals also drive o...

 td-cowen-downgrades-harpoon-therapeutics-to-market-perform

TD Cowen analyst Tara Bancroft downgrades Harpoon Therapeutics (NASDAQ:HARP) from Outperform to Market Perform.

 dow-surges-over-100-points-commercial-metals-posts-upbeat-q1-results

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow ...

 hc-wainwright--co-downgrades-harpoon-therapeutics-to-neutral-raises-price-target-to-23

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Harpoon Therapeutics (NASDAQ:HARP) from Buy to Neutral and...

 why-rxsight-shares-are-trading-higher-by-20-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24...

 crude-oil-falls-sharply-ambrx-biopharma-shares-spike-higher

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down...

 today-is-cancer-focused-deals-day-johnson--johnson-scoops-up-ambrx-biopharma-as-merck-boosts-cancer-portfolio-with-harpoon-deal

Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transa...

 us-stocks-mixed-nasdaq-jumps-over-100-points

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market ope...

Core News & Articles

HARP: 145% | Bloomberg Reported Earlier: Merck Is In Advanced Talks To Buy Harpoon Therapeutics For ~$23/Share ACON: 130% | Ac...

 why-lumiradx-shares-are-trading-lower-by-over-30-here-are-20-stocks-moving-premarket

Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will ...

 top-3-health-care-stocks-that-may-plunge-in-january

As of Jan. 8, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

 why-is-cancer-focused-harpoon-therapeutics-stock-shooting-higher-today

Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ: 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION